Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Vertex Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Accounts Payable
- The proportion of accounts payable relative to total liabilities and shareholders' equity fluctuated between 0.76% and 1.94% over the observed period. Initial values near 1% showed a notable increase starting in late 2022, peaking at 1.94% in March 2025, indicating a gradual rise in short-term obligations payable to suppliers.
- Accrued Expenses
- Accrued expenses consistently represented a significant portion, varying mainly between 11.6% and 15.13%. The ratio peaked early in the dataset before experiencing some volatility but generally hovered around 12% to 14% during the latter quarters, suggesting relatively stable accrued liabilities with occasional increases.
- Other Current Liabilities
- Other current liabilities displayed variability, ranging roughly between 1.3% and 2.71%. The data shows a pattern of mild fluctuation without a clear trend, implying transient changes in miscellaneous short-term liabilities.
- Current Liabilities (Aggregate)
- The total current liabilities as a share of total liabilities and equity varied moderately, mostly between 15% and 17.8%. A decline was noted in late 2020 and early 2021 before rising again towards the end of the monitored period, reflecting relative stability with intermittent shifts.
- Long-term Operating Lease Liabilities
- Emerging in 2020 at approximately 3%, long-term operating lease liabilities decreased progressively to around 1.5% by mid-2024. Subsequently, there was a sharp rise to over 7% in late 2024 and early 2025, which may suggest renewed or expanded lease commitments in the most recent quarters.
- Other Long-term Liabilities
- Other long-term liabilities demonstrated a gradual decline from about 10% to a low near 4.5%, with minor fluctuations. This steady decrease could indicate successful reduction or reclassification of longer-term obligations.
- Long-term Liabilities (Aggregate)
- Overall long-term liabilities generally declined from a high near 10% at the start of the period to about 6.5% before rising again sharply to almost 12% toward the end. The latter increase is largely attributable to the rise in operating lease liabilities, pointing to evolving long-term commitments.
- Total Liabilities
- Total liabilities decreased moderately from roughly 27% to around 22% in early 2024, then climbed back up to nearly 30% by late 2024 before stabilizing near 28%. This overall pattern reveals a period of liability reduction followed by an expansion in liabilities toward the end of the timeline.
- Common Stock
- The percentage of common stock remained stable and negligible, consistently around 0.01% to 0.03%, reflecting minimal changes in common stock relative to total equity and liabilities.
- Additional Paid-in Capital
- This component showed a marked decline over time, decreasing consistently from about 86.5% down to roughly 25% by mid-2025. The downward trend indicates a reduction in excess paid-in capital relative to total liabilities and equity, possibly due to capital management strategies or share repurchases.
- Accumulated Other Comprehensive Income (Loss)
- This ratio fluctuated near zero, showing periods of both slight gains and losses without a clear persistent trend. The values ranged approximately between -0.6% and 0.6%, implying minimal overall impact on equity structure.
- Retained Earnings (Accumulated Deficit)
- Retained earnings improved substantially, moving from a negative proportion (-14%) to a positive and increasing range exceeding 46% by early 2025. This reflects ongoing profitability and accumulation of earnings over the period.
- Shareholders’ Equity
- Shareholders' equity maintained a dominant share, generally between 70% and 77%. It showed a modest decline towards the end of the observation period but remained the major component within total liabilities and equity, indicating sustained financial strength.
- Total Liabilities and Shareholders’ Equity
- The total was consistently 100%, as expected, serving as the baseline for the relative analysis of components.